Preview

Rational Pharmacotherapy in Cardiology

Advanced search

MODERN ANTIPLATELET THERAPY OF ISCHEMIC HEART DISEASE PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS: DATA FROM EVIDENCE-BASED MEDICINE AND REAL PRACTICE

https://doi.org/10.20996/1819-6446-2011-7-3-319-322

Full Text:

Abstract

Aim. To study a rate of clopidogrel use in patients having indications for clopidogrel therapy according with up to date guidelines. Material and methods. Database of patients experienced acute myocardial infarction (MI) and database of patients experienced angiography because of stable ischemic heart disease (IHD) were used to evaluate clopidogrel therapy implementation. Patients with acute MI (n=84) and patients with IHD after angioplasty (n=239) were interviewed. Results. Only 14 of 84 (16.6%) patients after acute MI and 112 of 239 (47%) patients after angioplasty were taken clopidogrel within 12 months. Conclusion. The majority of patients after MI and coronary angioplasty do not receive clopidogrel despite the need of dual antiplatelet agents therapy.

About the Authors

S. Yu. Martsevich
State Research Center for Preventive Medicine I.M. Setchenov First Moscow State Medical University
Russian Federation


M. L. Ginzburg
Lyubertsy District Hospital № 2
Russian Federation


A. M. Malysheva
State Research Center for Preventive Medicine
Russian Federation


Yu. N. Polyanskaya
State Research Center for Preventive Medicine
Russian Federation


T. G. Kheliya
State Research Center for Preventive Medicine
Russian Federation


N. P. Kutishenko
State Research Center for Preventive Medicine
Russian Federation


References

1. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokianse, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 332: 349-360.

2. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of an-tipletelet therapy for prevention of death, myocardial infarction and stroke in high-risk patients. BMJ 2002; 324: 71-86.

3. CAPRIE Steering Committee. a randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339.

4. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.

5. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 2005; 366: 1607-1621.

6. Bhatt D., Fox K.A.A., Hacke W. et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-1717.

7. Bassand J.P., Hamm C.W., Ardissino D. et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007; 28: 1598-1660.

8. Van de Werf F., Bax J., Betriu A. et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Eur Heart J 2008; 29: 2909-2945.

9. 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. J Am Coll Cardiol 2011;57(19):e215-367.

10. Martsevich S.Yu., Ginzburg M.L., Kutishenko N.P. et al. A Lyubertsy study of mortality among patients with prior acute myocardial infarction: the first results of the LIS study. Klinicist 2011; 1: 24-27. Russian (Марцевич С.Ю., Гинзбург М.Л., Кутишенко Н.П. и др. Люберецкое исследование по изучению смертности больных, перенесших острый инфаркт миокарда. Первые результаты исследования "ЛИС". Клиницист 2011; 1: 24-27).

11. Gabinskiy Ya.L., Oslina V.P., Afanas'eva N.S. Plavix or zilt? Ural'skiy kardiologicheskiy zhurnal 2008; 3: 64-70. Russian (Габинский Я.Л., Ослина В.П., Афанасьева Н.С. Плавикс или зилт? Уральский кардиологический журнал 2008; 3: 64-70).

12. Martsevich S.Yu., Kutishenko N.P., Deev A.D. Original and generic drugs in cardiology. Can you solve the problem of interoperability? Vestnik Roszdravnadzora 2009; 4: 48-51. Russian (Марцевич С.Ю., Кутишенко Н.П., Деев А.Д. Оригинальные препараты и дженерики в кардиологии. Можно ли решить проблему взаимозаменяемости? Вестник Росздравнадзора 2009; 4: 48-51).

13. Rational pharmacotherapy in patients with cardiovascular disease. SCRF Recommendations. Kardiovaskulyarnaya terapiya i profilaktika 2009; 6 suppl 4: 1-56. Russian (Рациональная фармакотерапия больных с сердечно-сосудистыми заболеваниями. Рекомендации ВНОК. Кардиоваскулярная терапия и профилактика 2009; 6 приложение 4: 1-56).

14. Kutishenko N.P., Martsevich S.Yu., Vashurina I.V. What is a therapeutic equivalence of of generic drug and how to prove. Rational Pharmacother Card 2011;7(2):241-245. Russian (Кутишенко Н.П., Мар-цевич С.Ю., Вашурина И.В. Что такое терапевтическая эквивалентность воспроизведенного препарата (дженерика) и как ее доказать. РФК 2011;7(2):241-245).

15. Approved Drug Products with therapeutic equivalence evaluations (Orange Book), 31 edition. US FDA; 2011. page 544. Available on: http://www.fda.gov/downloads/Drugs/DevelopmentApproval-Process/UCM071436.pdf.


For citation:


Martsevich S.Yu., Ginzburg M.L., Malysheva A.M., Polyanskaya Yu.N., Kheliya T.G., Kutishenko N.P. MODERN ANTIPLATELET THERAPY OF ISCHEMIC HEART DISEASE PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS: DATA FROM EVIDENCE-BASED MEDICINE AND REAL PRACTICE. Rational Pharmacotherapy in Cardiology. 2011;7(3):319-322. (In Russ.) https://doi.org/10.20996/1819-6446-2011-7-3-319-322

Views: 335


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)